Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer

Surgical Oncology

Volumn 18, Issue 3, 2009, Pages 268-274

  Roberts, Wilmer B ^a   Han, Misop ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Biochemical recurrence; Prostate cancer; PSA recurrence; Radiation therapy; Radical prostatectomy; Salvage

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS;

EID: 68849114550     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2009.02.004     Document Type: Review

References (63)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
3. Ferguson R.A., Yu H., Kalyvas M., Zammit S., and Diamandis E.P. Ultrasensitive detection of prostate-specific antigen by a time- resolved immunofluorometric assay and the immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 42 (1996) 675-684
4. Simmons M.N., Stephenson A.J., and Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 51 (2007) 1175-1184
5. Djavan B., Milani S., and Fong Y.K. Benign positive margins after radical prostatectomy means a poor prognosis-pro. Urology 65 (2005) 218-220
6. Amling C.L., Blute M.L., Bergstralh E.J., Seay T.M., Slezak J., and Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164 (2000) 101-105
7. Ohori M., Goad J., Wheeler T., Eastham J., Thompson T., and Scardino P. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?. J Urol 152 (1994) 1843-1849
8. Partin A., Pound C., Clemens J., Epstein J., and Walsh P. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 20 (1993) 713-725
9. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., and Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523
10. Jhaveri F.M., Zippe C.D., Klein E.A., and Kupelian P.A. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 54 (1999) 884-890
11. Amling C., Bergstralh E., Blute M., Slezak J., and Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001) 1146-1151
12. Stephenson A.J., Kattan M.W., Eastham J.A., Dotan Z.A., Bianco Jr. F.J., Lilja H., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3973-3978
13. Scher H.I., Eisenberger M., D'Amico A.V., Halabi S., Small E.J., Morris M., et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group. J Clin Oncol 22 (2004) 537-556
14. Trapasso J., deKernion J., Smith R., and Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152 (1994) 1821-1825
15. Maffezzini M., Bossi A., and Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol 51 (2007) 605-613
16. D'Amico A.V., Chen M.-H., Roehl K.A., and Catalona W.J. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 23 (2005) 4975-4979
17. Patel R., Lepor H., Thiel R.P., and Taneja S.S. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. Urology 65 (2005) 942-946
18. Zhou P., Chen M.-H., McLeod D., Carroll P.R., Moul J.W., and D'Amico A.V. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992-6998
19. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
20. Dotan Z.A., Bianco Jr. F.J., Rabbani F., Eastham J.A., Fearn P., Scher H.I., et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23 (2005) 1962-1968
21. Liauw S.L., Webster W.S., Pistenmaa D.A., and Roehrborn C.G. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology 61 (2003) 1204-1210
22. Do T., Parker R., Do C., Tran L., Do L., and Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 4 (1998) 324-330
23. Chawla A.K., Thakral H.K., Zietman A.L., and Shipley W.U. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology 59 (2002) 726-731
24. Macdonald O.K., Schild S.E., Vora S.A., Andrews P.E., Ferrigni R.G., Novicki D.E., et al. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 58 (2004) 1530-1535
25. Pacholke H.D., Wajsman Z., Algood C.B., Morris C.G., and Zlotecki R.A. Postoperative adjuvant and salvage radiotherapy for prostate cancer: impact on freedom from biochemical relapse and survival. Urology 64 (2004) 982-986
26. Stephenson A.J., Shariat S.F., Zelefsky M.J., Kattan M.W., Butler E.B., Teh B.S., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
27. Katz M.S., Zelefsky M.J., Venkatraman E.S., Fuks Z., Hummer A., and Leibel S.A. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21 (2003) 483-489
28. Kim B.S., Lashkari A., Vongtama R., Lee S.P., and Parker R.G. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Genitourin Cancer 3 (2004) 93-97
29. Spiotto M.T., Hancock S.L., and King C.R. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69 (2007) 54-61
30. Lawton C.A., DeSilvio M., Roach Iii M., Uhl V., Kirsch R., Seider M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
31. Stephenson A.J., Scardino P.T., Kattan M.W., Pisansky T.M., Slawin K.M., Klein E.A., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007) 2035-2041
32. Buskirk S.J., Pisansky T.M., Schild S.E., Macdonald O.K., Wehle M.J., Kozelsky T.F., et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 176 (2006) 985-990
33. King C.R., Presti J.C., Gill H., Brooks J., and Hancock S.L. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys 59 (2004) 341-347
34. Tsai H.K., D'Amico A.V., Sadetsky N., Chen M.-H., and Carroll P.R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
35. Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., and Litwin M.S. And the urologic diseases in America project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
36. American Society for Therapeutic Radiology, Oncology consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
37. Roach Iii M., Hanks G., Thames J.H., Schellhammer P., Shipley W.U., Sokol G.H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
38. Thames H., Kuban D., Levy L., Horwitz E.M., Kupelian P., Martinez A., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
39. Sandler H.M., Dunn R.L., McLaughlin P.W., Hayman J.A., Sullivan M.A., and Taylor J.M.G. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48 (2000) 629-633
40. Rosser C.J., Chichakli R., Levy L.B., Kuban D.A., Smith L.G., and Pisters L.L. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 168 (2002) 536-541
41. Kuban D.A., Thames H.D., Levy L.B., Horwitz E.M., Kupelian P.A., Martinez A.A., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
42. Khuntia D., Reddy C.A., Mahadevan A., Klein E.A., and Kupelian P.A. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era. Cancer 100 (2004) 1283-1292
43. Crook J.M., Choan E., Perry G.A., Robertson S., and Esche B.A. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure. Urology 51 (1998) 566-572
44. Zagars G.K., and Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44 (1997) 213-221
45. Lee A.K., Levy L.B., Cheung R., and Kuban D. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63 (2005) 456-462
46. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., and Chen M.-H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
47. D'Amico A.V. Analysis of the clinical utility of the use of salvage brachytherapy in patients who have a rising PSA after definitive external beam radiation therapy. Urology 54 (1999) 201-203
48. Beyer D.C. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 54 (1999) 880-883
49. Grado G.L., Collins J.M., Kriegshauser J.S., Balch C.S., Grado M.M., Swanson G.P., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53 (1999) 2-10
50. Wong W.W., Buskirk S.J., Schild S.E., Prussak K.A., and Davis B.J. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 176 (2006) 2020-2024
51. Lee H.K., Adams M.T., and Motta J. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Brachytherapy 7 (2008) 17-21
52. Bong G., and Keane T. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can J Urol 14 (2007) 2-9
53. Pisters L.L., Perrotte P., Scott S.M., Greene G.F., and von Eschenbach A.C. Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 17 (1999) 2514
54. Izawa J.I., Madsen L.T., Scott S.M., Tran J.-P., McGuire E.J., von Eschenbach A.C., et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 20 (2002) 2664-2671
55. Ng C.K., Moussa M., Downey D.B., and Chin J.L. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol 178 (2007) 1253-1257
56. Ismail M., Ahmed S., Kastner C., and Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 100 (2007) 760-764
57. Greene G.F., Pisters L.L., Scott S.M., and Von Eschenbach A.C. Predictive value of prostate specific antigen nadir after salvage cryotherapy. J Urol 160 (1998) 86-90
58. de la Taille A., Hayek O., Benson M.C., Bagiella E., Olsson C.A., Fatal M., et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 55 (2000) 79-84
59. Sanderson K.M., Penson D.F., Cai J., Groshen S., Stein J.P., Lieskovsky G., et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 176 (2006) 2025-2032
60. Ward J.F., Sebo T.J., Blute M.L., and Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 173 (2005) 1156-1160
61. Bianco J.F.J., Scardino P.T., Stephenson A.J., DiBlasio C.J., Fearn P.A., and Eastham J.A. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 448-453
62. Liang C., Sebo T.J., Slezak J., Pisansky T.M., Bergstralh E.J., Neumann R.M., et al. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer 83 (1998) 2164-2171
63. Garzotto M., and Wajsman Z.E.V. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 159 (1998) 950-955